Clinical Features of COVID-19-Related Liver Functional Abnormality

Zhenyu Fan, Liping Chen, Jun Li, Xin Cheng, Jingmao Yang, Cheng Tian, Yajun Zhang, Shaoping Huang, Zhanju Liu, Jilin Cheng, Zhenyu Fan, Liping Chen, Jun Li, Xin Cheng, Jingmao Yang, Cheng Tian, Yajun Zhang, Shaoping Huang, Zhanju Liu, Jilin Cheng

Abstract

Background & aims: Some patients with SARS-CoV-2 infection have abnormal liver function. We aimed to clarify the features of COVID-19-related liver damage to provide references for clinical treatment.

Methods: We performed a retrospective, single-center study of 148 consecutive patients with confirmed COVID-19 (73 female, 75 male; mean age, 50 years) at the Shanghai Public Health Clinical Center from January 20 through January 31, 2020. Patient outcomes were followed until February 19, 2020. Patients were analyzed for clinical features, laboratory parameters (including liver function tests), medications, and length of hospital stay. Abnormal liver function was defined as increased levels of alanine and aspartate aminotransferase, gamma glutamyltransferase, alkaline phosphatase, and total bilirubin.

Results: Fifty-five patients (37.2%) had abnormal liver function at hospital admission; 14.5% of these patients had high fever (14.5%), compared with 4.3% of patients with normal liver function (P = .027). Patients with abnormal liver function were more likely to be male, and had higher levels of procalcitonin and C-reactive protein. There was no statistical difference between groups in medications taken before hospitalization; a significantly higher proportion of patients with abnormal liver function (57.8%) had received lopinavir/ritonavir after admission compared to patients with normal liver function (31.3%). Patients with abnormal liver function had longer mean hospital stays (15.09 ± 4.79 days) than patients with normal liver function (12.76 ± 4.14 days) (P = .021).

Conclusions: More than one third of patients admitted to the hospital with SARS-CoV-2 infection have abnormal liver function, and this is associated with longer hospital stay. A significantly higher proportion of patients with abnormal liver function had received lopinavir/ritonavir after admission; these drugs should be given with caution.

Keywords: ALP; Antiviral Drug; Liver Injury; Prognosis.

Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.

References

    1. Zhu N., Zhang D., Wang W. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733.
    1. Huang C., Wang Y., Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
    1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2[J] Nat Microbiol. 2020;5:536–544.
    1. World Health Organization WHO Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. Available at: Accessed February 20, 2020.
    1. Li Q., Guan X., Wu P. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199–1207.
    1. Chinese Center for Disease Control and Prevention. Available at: Accessed March 20, 2020.
    1. Wang D., Hu B., Hu C. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069.
    1. Chen N., Zhou M., Dong X. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513.
    1. Xiaoqiang Chai LH, Yan Zhang. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv 2020. Available at: 10.1101/2020.02.03.931766. Accessed February 20, 2020.
    1. Zhou P., Yang X.L., Wang X.G. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273.
    1. Xu Z., Shi L., Wang Y. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420–422.
    1. China National Health Commission Diagnosis and treatment scheme of new coronavirus infected pneumonia. 2020. Available at: Accessed February 20, 2020.
    1. Yang, Qingbin Lu, Mingjin Liu, et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. medRxiv 2020. Available at: 10.1101/2020.02.06.20020974. Accessed February 20, 2020.
    1. Novel Coronavirus Pneumonia Emergency Response Epidemiology T The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41:145–151.
    1. Bai Y., Yao L., Wei T. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020;323:1406–1407.
    1. Holshue M.L., DeBolt C., Lindquist S. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382:929–939.
    1. Guo Y., Korteweg C., McNutt M.A., Gu J. Pathogenetic mechanisms of severe acute respiratory syndrome. Virus Res. 2008;133:4–12.
    1. Shi X., Gong E., Gao D. Severe acute respiratory syndrome associated coronavirus is detected in intestinal tissues of fatal cases. Am J Gastroenterol. 2005;100:169–176.
    1. Farcas G.A., Poutanen S.M., Mazzulli T. Fatal severe acute respiratory syndrome is associated with multiorgan involvement by coronavirus. J Infect Dis. 2005;191:193–197.
    1. Lee N., Hui D., Wu A. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348:1986–1994.
    1. Assiri A., Al-Tawfiq J.A., Al-Rabeeah A.A. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013;13:752–761.
    1. Yancheva N., Tzonev R. A case of late presentation of darunavir-related cholestatic hepatitis. Int J STD AIDS. 2019;30:620–622.
    1. Jaeschke H., McGill M.R., Ramachandran A. Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity. Drug Metab Rev. 2012;44:88–106.
    1. Sherman K.E., Shire N.J., Cernohous P. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir. Clin Infect Dis. 2005;41:1186–1195.
    1. Chen J., Ling Y., Xi X. Efficacies of lopinavir/ritonavir and arbidol in the treatment of novel coronavirus pneumonia. Chin J Infect Dis. 2020;38:86–89.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever